Zevra Therapeutics, Inc. (ZVRA) Q4 FY25 Earnings Call

MyPlypha adoption and cash generation provide momentum, while enrollment variability and regulatory execution remain material uncertainties.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-10
Length48 minutes
EPS$1.16
Revenue$34.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

Read the full Q4 FY25 earnings call transcript

All ZVRA earnings · Back to ZVRA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.